Phase
Condition
Obesity
Diabetes Prevention
Treatment
Placebo
Semaglutide
Clinical Study ID
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Obesity (BMI ≥30 kg/m2) without or with controlled chronic conditions (e.g.,controlled hypertension).
Exclusion
Exclusion Criteria:
Weight changes greater than 3% in the previous 3 months
History of bariatric surgery including lap band and bariatric endoscopy
Significant untreated psychiatric dysfunction based upon screening with the HospitalAnxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score >11or difficulties with substance or eating disorders, the participant will be excludedand given a referral letter to his/her primary care doctor for further appraisal andfollow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during thepatient's lifetime, or any suicidal behavior in the last month.
Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
Any contraindication to FDA-approved GLP1R agonists
A person who is pregnant or wanting to become pregnant
Once the positive or negative cohort is filled at 2:1 ratio, some patients will bescreen failed if their gene cohort is full.
A family member who is enrolled in this study.
Principal Investigator Discretion
Study Design
Study Description
Connect with a study center
Mayo Clinic in Florida
Jacksonville, Florida 32224
United StatesActive - Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.